hereditary cancer
Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering
Premium
Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.
German Medical Center to Report Polygenic Risk Scores as Part of Clinical Whole-Genome Testing
Premium
Under the Ge-Med project, University Hospital Tübingen will offer diagnostic whole-genome sequencing for all genetic indications and will include PRS in its reporting.
NCCN Updates Guidelines Advising Against Using Polygenic Risk Scores Outside of Clinical Trials
The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.
Â
BRCA1/2 Population Screening Predicted to be Cost-Effective in Countries With Different Income Levels
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
Piper Sandler Initiates Coverage of Progenity With Overweight Rating
The coverage comes after the women's health diagnostics firm went public last month, seeking up to $100 million in the offering.